Helixgate https://validator.w3.org/feed/docs/rss2.html Kura spins diabetes work into a Lilly-backed biotech startup Tyra disappoints investors with bladder cancer data A booming business on Wall Street would love more biotechs to quietly die Cloverleaf: Turning 5-FU’s overlooked RNA mechanism into a new payload BrainChild: Bringing CAR Ts directly to the brain Eli Lilly’s pipeline in 2026: how the incretin boom is funding what comes next  Upcoming FDA approval decisions in Q4 2026 A translational framework for extrahepatic oligonucleotide delivery FDA grants RMAT designation to RiboX’s RXRG001 for xerostomia ADCs, mAbs, CAR Ts: One Bioluminescent Platform Measures Them All Gilead launches research facility in US for new medicine development Merck adds 53 to New Jersey chopping block The Multi-Attribute Method (MAM) as a Biologics Lifecycle Backbone NRAS Mutations May Require Mutation-Guided Combination Therapies Microscale Chromatography Moves Toward Manufacturing Readiness Novartis Shares Slide After Neuromuscular Candidate Acquired with Avidity Fails Phase III Trial No One-Size-Fits-All Solution for Autologous Cell Therapy Manufacturing Monoclonal Antibodies Targeting MMP-9 Alleviate Peripheral Neuropathy in Diabetic Mice Gene Therapy Extends Lifespan and Reduces Symptoms in Sandhoff Disease Cat Model Tozorakimab Demonstrated Statistically Significant and Highly Clinically Meaningful Reduction in COPD Exacerbations in OBERON and TITANIA Phase III Trials Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome Novartis Provides Update on Delpacibart Etedesiran (del-desiran) Phase III HARBOR Study for the Treatment of Myotonic Dystrophy Type 1 (DM1) Steady stream of crossover rounds stock biotech’s IPO pipeline Beyond China: Five other overseas destinations for biopharma dollars Solstice rises with $225M to develop next-gen CTLA-4 drug from China Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision Webinar: The Massive Scale of GLP-1s: Evolving Health, Healthcare and Markets FDA gains ‘continuity’ as Mikhail, Davis named permanent CBER, CDER leaders Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints Roivant’s pulmonary hypertension drug shines with ‘blowout’ Phase 2 data Inhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancer 2026 IPO stock tracker: How newly public biotechs are performing BMS clinches pivotal win for myeloma CAR T in ‘key derisking event’ AstraZeneca’s SERD pill overcomes adcomm defeat to win FDA nod in breast cancer Acting CBER, CDER heads become permanent as FDA works to restore stability Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease STAT+: Neuromuscular drug from Novartis fails in key study, adding to pressure on company STAT+: AstraZeneca’s experimental COPD treatment posts strong results in late-stage studies STAT+: Pharmalittle: We’re reading about an AstraZeneca COPD win, the FDA filling key jobs, and more STAT+: FDA warns an API supplier about residue on walls, a corroded product line, and open-toed sandals STAT+: Orexin discoverers awarded prestigious Lasker award Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off with phase 2 win Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpoint FDA gains ‘continuity’ as Mikhail, Davis named permanent CBER, CDER leaders Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durability BrainChild Bio masterminds $116M series A for CAR-T’s pivotal push in pediatric brain cancer Spyre’s 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 wins Pharvaris’ latest phase 3 win builds case for HAE drug with FDA verdict pending Home